[HTML][HTML] Promises and challenges of adoptive T-cell therapies for solid tumours
Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
Promises and challenges of adoptive T-cell therapies for solid tumours.
M Morotti, A Albukhari, A Alsaadi… - British Journal of …, 2021 - discovery.ucl.ac.uk
Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi… - British journal …, 2021 - mdanderson.elsevierpure.com
Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi, M Artibani… - British Journal of …, 2021 - ksascholar.dri.sa
Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
Promises and challenges of adoptive T-cell therapies for solid tumours.
M Morotti, A Albukhari, A Alsaadi, M Artibani… - British Journal of …, 2021 - europepmc.org
Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi, M Artibani… - British Journal of …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Cancer is a leading cause of death worldwide
and, despite new targeted therapies and immunotherapies, many patients with advanced …
and, despite new targeted therapies and immunotherapies, many patients with advanced …
Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi, M Artibani… - British Journal of …, 2021 - ora.ox.ac.uk
Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
[PDF][PDF] Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi, M Artibani… - 2021 - scienceopen.com
BACKGROUND Personalised, or precision, medicine aims to identify the optimal treatment
for each patient in order to maximise benefit and minimise toxicity. In the context of cancer …
for each patient in order to maximise benefit and minimise toxicity. In the context of cancer …
[PDF][PDF] Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi, M Artibani… - 2021 - academia.edu
BACKGROUND Personalised, or precision, medicine aims to identify the optimal treatment
for each patient in order to maximise benefit and minimise toxicity. In the context of cancer …
for each patient in order to maximise benefit and minimise toxicity. In the context of cancer …
Promises and challenges of adoptive T-cell therapies for solid tumours.
M Morotti, A Albukhari, A Alsaadi, M Artibani… - 2021 - crick.figshare.com
Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …